Welcome to
On Feet Nation
Posted by freeamfva on August 22, 2024 at 11:18pm 0 Comments 0 Likes
Posted by Akash Ra on August 22, 2024 at 11:18pm 0 Comments 0 Likes
Posted by Cassandra on August 22, 2024 at 11:14pm 0 Comments 0 Likes
Summary - A new market study, titled “Global Cystitis Market ” has been featured on WiseGuyReports.
The global Cystitis market is projected to reach around $XX billion by 2026 at a CAGR of approximately XX%, from 2018 to 2026, according to the XYZ market research company.
Source: Secondary Databases, Primary Interviews and XYZ Analysis
Market Overview:
Cystitis is usually not severe and may be awkward if left untreated, but may lead to complications. Bacterial infection most often causes cystitis. Cystitis is described as inflammation of the bladder, which is typically caused by bladder infection, according to the National Health Service. In the majority of cases, mild cystitis resolves within a couple of days. Usually Cystitis is caused if the urethra and bladder are infected with bacteria which are generally sterile or microbe-free. Bacteria attach to the bladder lining, resulting in irritating and inflaming the region.
ALSO READ: https://icrowdnewswire.com/2020/11/06/cystitis-market-2020-global-i...
Cystitis impacts both men and women of all ages. It is more prevalent in women than in men as women have smaller urethra. Roughly 80% of all UTIs are induced by bacteria from the bowel reaching the urinary tract. It is estimated that one in five females will have at least one UTI during their lifetime, according to the National Kidney Foundation. Almost 20% of females with a UTI will have another, and 30% will have one more. In view of the increasing incidence of cystitis, progress is required globally for patients.
Market Dynamics: Drivers, Restraints, Opportunities Challenges
• Increasing prevalence of UTI to drive the market for Cystitis
The infection of the urinary line is more frequent in females because of their anatomy than in males. More than once in their lives, several females experience urinary tract infection. Some studies suggest that the disease of the urinary tract impacts about 150 million individuals worldwide. Furthermore, about 11% of females visit a doctor in one year to receive therapy with urinary tract infections. Some of the primary triggers for urinary tract infection include hormonal modifications, inappropriate personal hygiene, catheter use, and other variables. The urinary tract infection market is projected to grow significantly in the next few years as the incidence of urinary tract infection increases.
• Use of urinary catheters and other drainage devices is likely to provide a boost to market growth in Cystitis.
The increasing incidence of chronic kidney disease, such as cancer of the bladder and renal failure, has resulted to increased use in patients of catheters and other drainage devices. Patients who use urinary catheters are more likely to get complex UTI. The danger of bacterium for patients using urinary catheters is about 5% per day, according to the World Health Organization (WHO), and 40% suffer from nosocomial infections. Some variables, such as extended catheterization length, failure to receive antibiotic system treatment, bacterial colonization in drainage bags, fast underlying fata illnesses, and others, are probable to lead to catheter-associated infection. Increasing the use of urinary catheters will therefore promote development in the market for therapy for cystitis infection.
Key Segments
Cystitis Market by Drug Class
• Penicillin and Combinations
• Quinolones
• Cephalosporin
• Aminoglycoside Antibiotics
• Sulphonamides (Sulfamethoxazole +Trimethoprim)
• Azoles and Amphotericin B
• Tetracycline (Doxycycline)
• Nirtofurans (Nitrofurantoin)
• Others
Cystitis Market by Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• E-commerce/ online Pharmacies
Geographic Landscape
• North America holds the major market share in terms of revenue during the forecast period.
In the global cystitis market is dominated by North America. The U.S. accounts for the prominent share in the market owing to high prevalence of disease in the region. Urinary tract infections are the most prevalent hospital-acquired infections in the U.S., particularly among urinary catheters patients. Followed by North America, Europe is also among the major shareholder in the global Cystitis market, owing to high adoption of innovative drugs and treatment. However, developing nations such as India, China, and South Korea have experienced development in the market for cystitis owing to increased awareness of urinary tract infection therapy and increased government spending on healthcare
Competitive Landscape:
The worldwide therapeutic market for urinary tract infection is extremely competitive and is made up of several significant players. Novartis AG, Pfizer, Merlion Pharma, GlaxoSmithKline PLC, Cipla, Inc., Bayer AG, AstraZeneca, Almirall SA and Merck & Co.,Inc.
Conclusion:
Factors such as increased UTI incidence, increased compliance with therapy, changing lifestyle patterns and favorable reimbursement policies in some nations are driving the development of the worldwide cystitis industry. The market is defined and fragmented by the existence of multiple suppliers. In regards to international branded drug manufacturers, several smaller businesses and those with a powerful position on the market for generic drugs also have a powerful stance on the market for cystitis therapy
FOR MORE DETAILS: https://www.wiseguyreports.com/reports/4532897-global-cystitis-market
About Us:
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
Contact Us:
NORAH TRENT
[email protected]
Ph: +162-825-80070 (US)
Ph: +44 203 500 2763 (UK)
© 2024 Created by PH the vintage.
Powered by
You need to be a member of On Feet Nation to add comments!
Join On Feet Nation